230 related articles for article (PubMed ID: 11829051)
1. New drug for prostate cancer.
Eur J Cancer Care (Engl); 2001 Jun; 10(2):79-80. PubMed ID: 11829051
[No Abstract] [Full Text] [Related]
2. [Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].
Matveev BP; Bukharkin BV
Urologiia; 2001; (6):20-1. PubMed ID: 11785074
[No Abstract] [Full Text] [Related]
3. [Adjuvant hormone therapy in prostatic cancer: after treatment with curative intent. The viewpoint of the urologist].
Martorana G
Recenti Prog Med; 2002 Mar; 93(3):179-82. PubMed ID: 11942170
[No Abstract] [Full Text] [Related]
4. [Adjuvant treatment of prostatic carcinoma after primary therapy. The "Early Prostate Cancer" Program].
Mansueto G; Longo F
Recenti Prog Med; 2002 Mar; 93(3):175-8. PubMed ID: 11942169
[No Abstract] [Full Text] [Related]
5. The third analysis of the bicalutamide Early Prostate Cancer programme.
Iversen P;
BJU Int; 2006 Mar; 97(3):438-9. PubMed ID: 16469002
[No Abstract] [Full Text] [Related]
6. [Efficacy of bicalutamide in adjuvant treatment of prostatic carcinoma after primary therapy with curative aim. The viewpoint of the surgeon].
Rigatti P; Scattoni V
Recenti Prog Med; 2002 Mar; 93(3):183-5. PubMed ID: 11942171
[No Abstract] [Full Text] [Related]
7. Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme.
Sternberg CN
BJU Int; 2006 Mar; 97(3):435-8. PubMed ID: 16469001
[No Abstract] [Full Text] [Related]
8. [Antiandrogen in prostate cancer].
Maeda O; Usami M
Nihon Rinsho; 2002 Dec; 60 Suppl 11():188-92. PubMed ID: 12599569
[No Abstract] [Full Text] [Related]
9. [Monotherapy with casodex at a dose of 150 mg--a new method of hormonal treatment of disseminated prostatic cancer].
Rusakov IG; Alekseev BIa
Urologiia; 2002; (5):23-6. PubMed ID: 12402771
[No Abstract] [Full Text] [Related]
10. [The use of Casodex (bicalutamide) in the treatment of disseminated prostatic cancer].
Sivko AV; Prokhorov AV
Urol Nefrol (Mosk); 1997; (3):49-52. PubMed ID: 9245060
[No Abstract] [Full Text] [Related]
11. Bicalutamide ('Casodex') development: from theory to therapy.
Kolvenbag GJ; Furr BJ
Cancer J Sci Am; 1997; 3(4):192-203. PubMed ID: 9263623
[No Abstract] [Full Text] [Related]
12. [Hormonal treatment of cancer of the prostate: review and present status].
Ganzer R; Wieland WF; Bach T; Rössler W; Blana A
Dtsch Med Wochenschr; 2007 Jan; 132(4):161-6. PubMed ID: 17230333
[No Abstract] [Full Text] [Related]
13. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
Moul JW
Cancer; 2009 Aug; 115(15):3376-8. PubMed ID: 19484788
[No Abstract] [Full Text] [Related]
14. 'Casodex': defining the role of antiandrogens.
McCaffrey JA; Scher HI
Cancer J Sci Am; 1997; 3(4):204-8. PubMed ID: 9263624
[No Abstract] [Full Text] [Related]
15. New molecules and treatment modulation in advanced prostatic cancer.
Mahler C; Verhelst J; Denis L
Acta Urol Belg; 1996 May; 64(2):95-8. PubMed ID: 8701825
[No Abstract] [Full Text] [Related]
16. [Bicalutamide].
Taéron C
Rev Infirm; 2010 Mar; (158):47-9. PubMed ID: 20383962
[No Abstract] [Full Text] [Related]
17. [Bicalutamide].
Kotake T
Nihon Rinsho; 2000 Jul; 58 Suppl():216-22. PubMed ID: 11022717
[No Abstract] [Full Text] [Related]
18. Bicalutamide 150 mg: practical prescribing in patients with early prostate cancer.
Anderson J
BJU Int; 2004 Oct; 94(6):758-9. PubMed ID: 15476502
[No Abstract] [Full Text] [Related]
19. The place and the results of monotherapy.
Bonnet P
Acta Urol Belg; 1998 May; 66(2):11-5. PubMed ID: 9633120
[No Abstract] [Full Text] [Related]
20. [Total androgen blockade].
Namiki M; Mizokami A
Nihon Rinsho; 2002 Dec; 60 Suppl 11():193-8. PubMed ID: 12599570
[No Abstract] [Full Text] [Related]
[Next] [New Search]